Skip to main content
SpringerLink
Log in
Book cover

Peripheral Actions of Dopamine pp 174–185Cite as

Drug Design for Cardiovascular Therapeutics: Activation of DA1 Receptors

  • Chapter

  • 9 Accesses

Abstract

The therapeutic rationale for the utility of drugs to be designed to selectively stimulate DA receptors was that such agents would be selective vasodilators. Because DA receptors were known to mediate vasodilatation and were believed to have a selective distribution in vascular beds such as the renal vasculature, it followed that these drugs might reduce blood pressure or load on the heart without an equivalent decline in kidney blood flow or renal function (Hahn et al., 1982; Goldberg and Raijfer, 1985). Thus, potential therapeutic targets were hypertension, congestive heart failure and conditions associated with reduced renal blood flow and increased renal vascular resistance.

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ackerman, D. M., Weinstock, J. W., Wiebelhaus, V. D. and Berkowitz, B. (1982). Renal vasodilators and hypertension. Drug Dev. Res., 2, 283–297

    Article  CAS  Google Scholar 

  • Berkowitz, B. A., Arleth, A. J., Sung, C.-P., Kruse, L. I., DeWolf, W. E. and Ohlstein, E. H. (1988). Effects of the novel dopamine-β-hydroxylase inhibitor, SK&F 102698, on catecholamine and blood pressure in spontaneously hypertensive rats. J. Pharmac. Exp. Ther. (in press)

    Google Scholar 

  • Berkowitz, B. A. and Ohlstein, E. H. (1984). Cardiovascular dopamine receptors: Recent advances in agonists and antagonists of the DA1-receptor. J. Cardiovasc. Pharmac., 6, S559–S563

    Article  CAS  Google Scholar 

  • Berkowitz, B. A. and Ohlstein, E. H. (1987). Fenoldopam. In A. Scriabine (Ed.), New Cardiovascular Drugs 1987, Raven Press, New York, pp. 237–250

    Google Scholar 

  • DeVries, G. W., Mobasser, A. and Wheeler, L. A. (1986). Stimulation of endogenous cyclic AMP levels in ciliary body by SK&F 82526, a novel dopamine receptor agonist. Curr. Eye Res., 5, 449–455

    Article  CAS  Google Scholar 

  • Dupont, A. G., Lefebvre, R. A. and Vanderniepen, P. (1987). Influence of the dopamine receptor agonists fenoldopam and quinperole in the rat superior mesenteric vascular bed. Br. J. Pharmac., 91, 493–501

    Article  CAS  Google Scholar 

  • Flaim, K. E., Gessner, G. A., Crooke, S. T., Sarau, H. M. and Weinstock, J. (1985). Binding of a novel dopaminergic agonist radioligand and (3H) fenoldopam (SK&F 82526) to D1 receptors in rat striatum. Life Sci., 36, 1427–1436

    Article  PubMed  CAS  Google Scholar 

  • Foley, J. J. and Sarau, H. M. (1984). Adrenergic binding studies of SK&F 82526 and its enantiomers. Fed. Proc., 43, 555

    Google Scholar 

  • Goldberg, L., Kohli, J. P. and Glock, D. (1986). DA1 agonist versus alpha-adrenoceptor antagonist activity of fenoldopam in the dog. Fed. Proc., 45, 195

    Google Scholar 

  • Goldberg, L. and Raijfer, S. I. (1985). Dopamine receptors: Applications in clinical cardiology. Circulation, 72, 245–248

    Article  PubMed  CAS  Google Scholar 

  • Hahn, R. A., Wardell, J. R., Sarau, H. M. and Ridley, P. T. (1982). Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. J. Pharmac. Exp. Ther., 233, 305–313

    Google Scholar 

  • Harvey, J. N., Worth, D. P., Brown, J. and Lee, M. R. (1986). Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension. Br. J. Clin. Pharmac., 21, 53–61

    Article  CAS  Google Scholar 

  • Hughes, A., Thorn, S., Martin, G., Redman, D., Hasan, S. and Sever, P. (1986). The action of a dopamine (DA1) receptor agonist, fenoldopam, in human vasculature in vivo and in vitro. Br. J. Clin. Pharmac, 22, 535–540

    Article  CAS  Google Scholar 

  • Lappe, R., Todt, J., and Wendt, R. (1986). Effect of fenoldopam on regional vascular resistance in conscious spontaneously hypertensive rats. J. Pharmac. Exp. Ther., 236, 187–191

    CAS  Google Scholar 

  • Lokhandwala, M. F. and Sabouni, M. H. (1985). Ganglionic dopamine receptors as mediators of the inhibition of neurogenic vasoconstriction produced by fenoldopam. J. Autonom. Pharmac., 5, 301–305

    Article  CAS  Google Scholar 

  • Molinoff, P., Brimijoin, S. and Axelrod, J. (1972). Induction of dopamine β-hydroxylase and tyrosine hydroxylase in rat hearts and sympathetic ganglia. J. Pharmac. Exp. Ther., 182, 116–129

    CAS  Google Scholar 

  • Ohlstein, E. H., Kruse, L. I., Ezekiel, M., Sherman, S. S., Erickson, R., DeWolfe, W. E. and Berkowitz, B. A. (1987). Cardiovascular effects of a new potent dopamine β-hydroxylase inhibitor in spontaneously hypertensive rats. J. Pharmac. Exp. Ther., 241, 554–559

    CAS  Google Scholar 

  • Ohlstein, E. H., Zabko-Potapovich, B. and Berkowitz, B. A. (1984). Studies on vascular dopamine receptors with dopamine receptor agonist: SK&F 82526. J. Pharmac. Exp. Ther., 229, 433–439

    CAS  Google Scholar 

  • Ohlstein, E. H., Zabko-Potapovich, B. and Berkowitz, B. A. (1985). The DA1 receptor agonist fenoldopam (SK&F 82526) is also an α 2-adrenoceptor antagonist. Eur. J. Pharmac., 118, 321–329

    Article  CAS  Google Scholar 

  • Roffman, M., Friedman, L. and Goldstein, M. (1973). The effect of acute and chronic swim stress on dopamine β-hydroxylase activity. Life Sci., 12, 369–376

    Article  CAS  Google Scholar 

  • Sole, M. J., Kamble, A. B. and Hussain, M. M. (1977). A possible change in the rate limiting steps for cardiac norepinephrine synthesis in the cardiomyopathetic Syrian hamster. Clin. Res., 41, 814–817

    CAS  Google Scholar 

  • Stote, R., Dubb, J., Familiar, R., Erb, B. and Alexander, F. (1983). A new oral vasodilator SK&F 82526. Clin. Pharmac. Ther., 34, 309–315

    Article  CAS  Google Scholar 

  • Szabo, B., Hedler, L. and Starke, K. (1986). Dopamine receptor agonist and alpha-2 adrenoceptor antagonist effects of fenoldopam in rabbits. J. Pharmac. Exp. Ther., 239, 881–886

    CAS  Google Scholar 

  • Trajkov, T., Berkowitz, B. A. and Spector, S. (1974). Catechol-o-methyltransferase and dopamine β-hydroxylase activity in the blood vessels of hypertensive rats. Blood Vessies, 11, 101–109

    CAS  Google Scholar 

  • Weiner, N. (1985). In Gilman, A. G., Goodman, L. S., Rall, T. W. and Murad, F. (Eds.) The Pharmacological Basis of Therapeutics, Macmillan., New York, p. 210

    Google Scholar 

Download references

Authors
  1. Barry A. Berkowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Physiology, University of Melbourne Medical Centre, Australia

    Christopher Bell

  2. Department of Medicine, Monash University Medical Centre, Australia

    Barry McGrath

Copyright information

© 1988 Barry A. Berkowitz

About this chapter

Cite this chapter

Berkowitz, B.A. (1988). Drug Design for Cardiovascular Therapeutics: Activation of DA1 Receptors. In: Bell, C., McGrath, B. (eds) Peripheral Actions of Dopamine. Satellite Symposia of the IUPHAR 10th International Congress of Pharmacology. Palgrave, London. https://doi.org/10.1007/978-1-349-09503-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-349-09503-2_11

  • Publisher Name: Palgrave, London

  • Print ISBN: 978-1-349-09505-6

  • Online ISBN: 978-1-349-09503-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation